No Difference in Mortality between Terlipressin and Somatostatin Treatments in Cirrhotic Patients with Esophageal Variceal Bleeding and Renal Functional Impairment
學年 105
學期 1
出版（發表）日期 2016-11-01
作品名稱 No Difference in Mortality between Terlipressin and Somatostatin Treatments in Cirrhotic Patients with Esophageal Variceal Bleeding and Renal Functional Impairment
作品名稱（其他語言）
著者 Hung, Tsung-Hsing; Tsai, Chen-Chi; Tseng, Chih-Wei; Tseng, Kuo-Chih; Hsieh, Yu-Hsi; Tsai, Chih-Chun
單位
出版者
著錄名稱、卷期、頁數 European Journal of Gastroenterology & Hepatology 28(11), p.1275–1279
摘要 Objective To study the differences in mortality between terlipressin and somatostatin treatments in cirrhotic patients with esophageal variceal bleeding (EVB) and renal functional impairment (RFI). Methods The National Health Insurance Database, part of the Taiwan National Health Insurance Program, was used to enroll cirrhotic patients who had received endoscopic variceal ligation plus somatostatin or terlipressin for EVB and who were hospitalized between 1 January 2007 and 31 December 2010. The differences in mortality between the two vasoactive agents were compared and the risk factors for 30-day mortality because of EVB were identified. Results A total of 2324 cirrhotic patients with EVB were enrolled. The 30-day mortality data showed no significant differences between the somatostatin and the terlipressin groups (P=0.232). The risk of 30-day mortality was significantly higher in male patients [hazard ratio (HR): 1.50, P=0.002] and patients with hepatic encephalopathy (HR: 1.82, P<0.001), ascites (HR: 1.32, P=0.008), bacterial infections (HR: 2.10, P<0.001), hepatocellular carcinoma (HR: 2.09, P<0.001), and RFI (HR: 3.89, P<0.001). A subgroup analysis of cirrhotic patients with RFI was carried out. The overall 30-day mortality was higher in patients treated with somatostatin than in those treated with terlipressin (52.6 vs. 42.3%), but the difference failed to reach significance (adjust HR: 1.49, 95% confidence interval: 0.94–2.37, P=0.091). Conclusion RFI was the most important risk factor for 30-day mortality in EVB patients. Terlipressin and somatostatin had similar effects on 30-day mortality in cirrhotic patients with EVB and RFI.
關鍵字 esophageal variceal bleeding;renal function impairment;somatostatin;terlipressin
語言 en
ISSN 0954-691X
期刊性質 國外
收錄於 SCI
產學合作
通訊作者 Tseng, Chih-Wei
審稿制度 否
國別 GBR
公開徵稿
出版型式 ,電子版
相關連結

機構典藏連結 ( http://tkuir.lib.tku.edu.tw:8080/dspace/handle/987654321/109463 )

SDGS 良好健康和福祉